HealthyWay Inc. Announces Major Change in Use of IPO Proceeds: Strategic Shift to AI & Digital Healthcare

HealthyWay Inc. (HKEX: 2587) has issued a significant update regarding the allocation and use of its IPO proceeds, marking a major strategic pivot towards artificial intelligence (AI) and digital healthcare services. The announcement clarifies previous misstatements in its June 2026 update and outlines a comprehensive reallocation of funds originally intended for more traditional business expansion, such as physical pharmacy growth and direct recruitment.

Key Highlights for Investors

• Substantial Reallocation of IPO Proceeds: The company has reallocated virtually all unutilised IPO proceeds (over HK\$106 million) away from expanding physical specialty pharmacies and manpower-based business development, directing these funds into the development and deployment of AI digital employee technologies, ecosystem development, and technology infrastructure.
• Clarification of Financial Figures: Previous figures related to the unutilised proceeds were misstated. The corrected figures show that as of the latest announcement, only HK\$2.71 million had been used, leaving HK\$106.69 million to be reallocated.
• Suspension of Offline Pharmacy Expansion: Due to increased competition, declining margins, and the rapid rise of online pharmaceutical retail, the company is suspending further investment in offline pharmacy networks in favour of digital solutions.
• AI-Driven Transformation: HealthyWay has made strong advances in AI “digital employee” technologies, including AI sales assistants, medical assistants, and health managers, which now form the core of its operational strategy.
• Prudent Investment Approach: The company has not identified any suitable acquisition targets and will retain a conservative approach towards strategic investments, shifting the focus to technology-enabled health businesses rather than traditional pharmacies or pharmaceutical R&D companies.
• Ecosystem and Regional Expansion: The company plans to establish 10 to 20 new regional ecosystem entities across China with local partners to accelerate market penetration for its AI-driven healthcare and marketing services.

Details of the Changes

1. Allocation Breakdown

2. Strategic and Operational Context

• AI-Driven Cost Efficiency: HealthyWay’s rapid advances in AI allowed automation of functions previously performed by large teams of on-site health assistants and business development staff. AI digital employees now perform critical sales, patient management, and consultation-support roles, greatly increasing efficiency and scalability.
• Market and Policy Changes: The offline pharmacy sector saw declining gross margins (from 10.21% in 2024 to 9.23% in 2025), intense competition, and the closure of 22,000 pharmacies in 2025. Meanwhile, online pharmaceutical sales surged (RMB96.5 billion sales in 2025, up 35% YoY), with policy support for online medical insurance and electronic prescriptions.
• Shift in Investment Focus: Strategic investments will now target health product and healthcare service providers, especially those with synergies in AI, big data, real-world studies, and hospital support functions.
• R&D Optimization: The company will reduce its planned IT recruitment, as AI-assisted development tools have increased the productivity of existing staff. Resources will instead be used for AI platforms, cloud computing, and technical infrastructure.
• Regional Ecosystem Companies: HealthyWay will set up up to 20 new regional entities in partnership with local operators, focusing on region-specific digital marketing, content, and healthcare IT services, with investment per entity ranging from RMB0.5 to 3 million.

Shareholder Implications and Price-Sensitive Information

• Major Strategic Pivot: The company’s strong move away from offline, labor-intensive expansion to technology-driven, AI-enabled healthcare services may materially impact future profitability and growth prospects. This is a clear response to changing industry dynamics and the company’s improving AI capabilities.
• Reduced Exposure to Low-Margin Businesses: By suspending offline pharmacy expansion and focusing on digital and AI-enabled services, the company is aiming to improve margins and operational efficiency.
• Potential for Rapid Scalability: The new AI-driven business model could enable much faster and lower-cost expansion, especially as the company partners with local operators for regional growth.
• Prudent Capital Management: Investors should note that no major acquisition targets have yet been identified, indicating careful stewardship of IPO funds.
• Revenue Mix Shift: The company’s revenue is increasingly derived from corporate services and digital marketing (86.8% of 2025 revenue), while health and medical services now represent a smaller portion (13.2%).

Management Commentary

The Board emphasizes that this reallocation is not a change in overall strategy but a refinement of resource deployment. The intent is to align with technological advancements and market opportunities, increasing competitiveness and efficiency while responding to evolving healthcare industry trends.

The Board states that the reallocation is fair, reasonable, and in the interests of the company and its shareholders.

Conclusion

This announcement marks a pivotal moment for HealthyWay Inc., with a decisive shift in capital deployment toward scalable, AI-driven healthcare solutions. Investors should closely monitor implementation progress, potential partnerships, and developments in AI healthcare applications, as these may have material impacts on the company’s future growth trajectory and share value.

Disclaimer: The above article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consider their own financial circumstances before making any investment decisions. The information is based on disclosures from HealthyWay Inc. as of 29 July 2026 and may be subject to change.

健康之道有限公司（HealthyWay Inc.）公布IPO集資用途重大調整　全面轉向AI及數字健康服務

健康之道有限公司（HKEX: 2587） 最近公布了關於IPO集資用途的重大調整，顯示公司戰略明顯轉型，全面投向人工智能（AI）及數字健康服務。公告澄清了早前6月公告中的未用資金數據錯誤，並詳細列出資金由傳統業務（如線下藥房及大規模招聘）轉向AI和生態系統發展的分配方案。

投資者關注重點

• 集資用途大幅重新分配： 公司已把絕大部分未用IPO資金（逾1.06億港元）由拓展線下專科藥房及人手招聘，轉投AI數字員工技術、生態系統及科技基建。
• 財務數據澄清： 早前公告中的未用資金數據有誤，現更正為截至公告日僅動用271萬港元，餘下1.0669億港元將重新分配。
• 暫停線下藥房擴張： 由於競爭加劇、毛利下滑及網上藥品零售急升，公司決定暫停線下藥房投資，改以數字化方式拓展市場。
• AI驅動轉型： 公司AI「數字員工」技術進展迅速，包括AI銷售助手、醫療助手及健康經理，已成營運核心。
• 審慎投資策略： 暫未找到合適的收購對象，公司將資金聚焦於技術型健康業務，而非傳統藥房或藥企研發。
• 生態系統及區域擴張： 公司計劃於全國設立10至20間區域生態公司，與本地夥伴合作，加快AI健康及營銷服務的滲透。

調整詳情

• AI提升效率： AI技術令原本需大量人手的銷售、患者管理等工作自動化，服務效率及可擴展性大幅提升。
• 市場與政策變化： 線下藥房毛利率由2024年的10.21%降至2025年的9.23%，同年全國關閉藥房達2.2萬間；網上藥品銷售2025年達965億元人民幣（同比增長35%），政策亦支持網上醫保及電子處方。
• 投資重點轉向： 未來投資將主攻健康產品/服務供應商，尤其與AI、大數據、真實世界研究及醫院支援相關企業。
• 研發資源優化： AI輔助開發工具提升現有IT人員效能，減少對大規模招聘需求，資源將投放於AI平台、雲計算及技術基建。
• 區域生態公司： 公司將與本地夥伴合作，設立最多20間區域公司，專注於本地化數字營銷、內容及醫療IT服務，每間投資額0.5至300萬元人民幣。

對股東及股價的潛在影響

• 策略大轉型： 明確由人手密集型業務轉型為技術驅動型AI健康服務，或顯著影響公司未來盈利能力及增長潛力。
• 減少低毛利業務曝險： 暫停線下藥房擴張，集中發展數字化高效業務，有望改善利潤率。
• 擴張速度提升： 新AI驅動業務模式可更快低成本拓展，尤其通過本地合作夥伴滲透各區市場。
• 審慎理財： 公司暫未落實大型收購目標，顯示對IPO資金運用審慎。
• 收入結構變化： 2025年公司收入86.8%來自企業服務及數字營銷，健康及醫療服務僅佔13.2%。

管理層評論

董事會強調，今次調整並非戰略改變，而是資源部署的優化，旨在配合科技進展和市場需求，提升競爭力及運營效率。

董事會認為，資金重新分配公平合理，符合公司及全體股東利益。

總結

公司今次公告標誌著戰略重大轉型，IPO資金決定性投向可擴展的AI醫療服務。投資者應密切關注AI應用落地、區域合作及技術進展，這些均可能對公司增長及股價帶來重大影響。

免責聲明： 以上內容僅供參考，並不構成任何投資建議。投資者應根據自身情況審慎決策。資料根據健康之道有限公司截至2026年7月29日披露，或會隨時更改。

View HEALTHYWAY INC Historical chart here